How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?

被引：0
作者：
Linda E. Coate
Natasha B. Leighl
机构：
[1] Princess Margaret Hospital,Division of Medical Oncology
来源：
Current Treatment Options in Oncology | 2011年 / 12卷
关键词：
Epidermal Growth Factor Receptor; Bevacizumab; Docetaxel; Cetuximab; Gefitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
As the treatment of non-small cell lung cancer (NSCLC) evolves to include more targeted therapies, costs of treatment have increased significantly. Advances in NSCLC treatment include longer survival duration, and in some cases, better progression-free survival and quality of life, and the potential for decreased toxicity. Through pharmacoeconomic analyses, payors seek to value the improvements in outcomes from novel therapies, and relate these improvements to their costs. In NSCLC, three categories of novel agents have been introduced into clinical practice: (1) agents targeting the epidermal growth factor receptor (EGFR); (2) agents targeting the vascular endothelial growth factor (VEGF) and (3) novel chemotherapy agents, specifically pemetrexed. Here we review published economic analyses for these agents in lung cancer, and their potential impact on treatment decisions.
引用
收藏
页码：1 / 11
页数：10
相关论文
共 106 条
[1]  
Jemal A(2008)Cancer statistics, 2008 CA Cancer J Clin 58 71-96
[2]  
Siegel R(2010)Targeted cancer therapies Nat Rev Drug Discov 9 427-428
[3]  
Ward E(2006)Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[4]  
Aggarwal S(2008)Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab? J Thorac Oncol 3 S283-1234
[5]  
Sandler A(2009)Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227-1531
[6]  
Gray R(2009)Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 1525-917
[7]  
Perry MC(2010)Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099 J Clin Oncol 28 911-3551
[8]  
Herbst RS(2008)Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 3543-957
[9]  
Sandler A(2009)Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 947-2388
[10]  
Reck M(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-3283
12345678910